Ocular Therapeutix Q2 2023 DEXTENZA revenue $15M (+24% YoY), net loss $20.7M, $82.5M credit facility closed

OCULAR THERAPEUTIX, INC

2023-Q2 EPS reported -$0.66 revenue$28,561,000

DEXTENZA net product revenue $15.0M in Q2 2023, up 24% from $12.1M in Q2 2022 and 14% sequentially.
Total net revenue $15.2M, up 24% YoY; net loss $(20.7)M or $(0.26) per share vs. $(18.8)M loss in Q2 2022.
Closed $82.5M Barings credit facility; net cash proceeds ~$51.6M after repayment of MidCap debt; cash runway extended into 2025.
First pivotal trial for OTX-TKI in wet AMD expected to initiate in Q3 2023; HELIOS Phase 1 NPDR trial enrollment completed.
Full-year 2023 DEXTENZA revenue guidance expected to be upper end of $55M-$60M range; board added Dr. Adrienne Graves in July 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

OCULAR THERAPEUTIX, INC reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-088335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.